Trial Profile
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Deucravacitinib (Primary) ; Apremilast
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms POETYK PSO-1
- Sponsors Bristol-Myers Squibb
- 16 Jan 2024 Results from NCT04036435, NCT03611751 and NCT03624127, evaluating deucravacitinib safety and efficacy over 2 years in patients, published in the British Journal of Dermatology
- 20 Dec 2023 Results of secondary analysis evaluating meaningful within-patient score change thresholds for the PSSD using data from this study evaluating the Efficacy and Safety of Deucravacitinib, published in the JAMA Dermatology
- 18 Dec 2023 Results from POETYK PSO-1 and PSO-2 evaluating the efficacy and safety of deucravacitinib in scalp psoriasis , published in the Journal of the American Academy of Dermatology